SGLT2 inhibitors used less frequently in HFrEF patients despite potential CV benefits: JAMA Medha Baranwal24 May 2023 10:30 AM ISTUSA: A recent study published in JAMA Cardiology found low rates of SGLT2 inhibitors for HFrEF (heart failure with reduced ejection fraction) in the...
Patiromer use lower hyperkalemia risk in HFrEF patients: DIAMOND trial Medha Baranwal5 Aug 2022 8:00 PM ISTUSA: Simultaneous use of patiromer and high-dose mineralocorticoid receptor antagonist (MRA) lowers the risk of recurrent hyperkalemia in patients...
Tailored Electronic Health Record Improves Optimal Care For HF Patients: PROMPT-HF Trial MD Bureau7 April 2022 6:00 AM ISTHeart failure with reduced ejection fraction (HFrEF) is one of the most common chronic illnesses in the United States and carries a significant risk...
Guideline-directed medical therapy not good enough for Highly Frail Patients with HFrEF MD Bureau18 March 2022 9:00 AM ISTGuidelines strongly recommend patients with heart failure with reduced ejection fraction (HFrEF) be treated with multiple medications proven to...
Dapagliflozin appears beneficial at various levels of Heart Failure in HFrEF patients: Study Dr. Shravani Dali10 Dec 2021 9:00 AM ISTDapagliflozin appears beneficial at various levels of Heart Failure with Reduced Ejection Fraction, according to a study published in the ...
MRA Strongly Recommended in Treatment of Heart Failure with Reduced Ejection Fraction: 2021 ESC Guidelines Medical Dialogues Bureau17 Nov 2021 12:45 PM ISTPharmacotherapy is the cornerstone of treatment for Heart Failure with Reduced Ejection Fraction (HFrEF) and should be implemented before considering...
Dapagliflozin reduces risk for hyperkalemia in HFrEF patients treated with MRAs: Study Dr. Shravani Dali20 Aug 2021 9:00 AM ISTDapagliflozin Reduces Hyperkalemia Risk in Heart Failure and reduced ejection fraction (HFrEF) in patients treated with mineralocorticoid receptor...
Omecamtiv mecarbil reduces CV death, heart failure risk in HFrEF patients: NEJM Medha Baranwal14 Jan 2021 8:21 PM ISTUSA: The administration of omecamtiv mecarbil in patients with heart failure and a reduced ejection fraction (HFrEF) reduces the risk of a composite...
SGLT2 inhibitors improve survival and renal outcomes in heart failure: Lancet Medha Baranwal16 Sept 2020 7:50 AM ISTFrance: Treatment with empagliflozin and dapagliflozin reduces all-cause mortality and improves renal outcomes in patients with heart failure with...
FDA grants fast Track designation to omecamtiv mecarbil for HFrEF Dr. Kamal Kant Kohli9 May 2020 9:09 AM ISTTHOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO--Heart failure is a serious condition that affects more than 64 million people worldwide about half of...
